List of works - Kirsten B Goldberg

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC)

scientific article published on 09 November 2020

FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer

scientific article published on 26 March 2020

FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer

scientific article published on 09 November 2020

FDA Approval Summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma

scientific article published on 02 November 2020

FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1

scientific article published on 30 January 2020

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults

scientific article published on 23 August 2019

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

scientific article published on 22 September 2020

FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia

scientific article published on 07 May 2019

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

scientific article published on 28 January 2019

FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer

scientific article published on 24 October 2019

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

scientific article published on 23 September 2019

FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer

scientific article published on 14 October 2020

Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.

scientific article

Regulatory Considerations for Contribution of Effect of Drugs used in Combination Regimens: Renal Cell Cancer Case Studies

scientific article published on 30 July 2020

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications

scientific article published on 01 January 2018

The FDA Oncology Center of Excellence and precision medicine.

scientific article published in January 2017

List of works by Kirsten B Goldberg